Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Abstract

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

Individual Disclosures for the NCCN Esophageal and Esophagogastric Junction Cancers Panel

TU1
  • 1.

    Torre LA, Siegel RL, Ward EM, . Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev 2016;25:16–27.

    • Search Google Scholar
    • Export Citation
  • 2.

    World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: oesophagus cancer fact sheet. 2018. Available at: http://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf. Accessed January 22, 2019.

    • Export Citation
  • 3.

    Torre LA, Bray F, Siegel RL, . Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.

  • 4.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.

  • 5.

    World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: United States of America cancer fact sheet. 2018. Available at: http://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-fact-sheets.pdf. Accessed January 22, 2019.

    • Export Citation
  • 6.

    Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007;17:38–44.

  • 7.

    Amin MB, Edge SB, Greene FL, editors. AJCC cancer staging manual, 8th Ed. Springer, New York, NY. 2017.

  • 8.

    Turati F, Tramacere I, La Vecchia C, . A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013;24:609–617.

    • Search Google Scholar
    • Export Citation
  • 9.

    Ryan AM, Duong M, Healy L, . Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011;35:309–319.

    • Search Google Scholar
    • Export Citation
  • 10.

    Engel LS, Chow W-H, Vaughan TL, . Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404–1413.

    • Search Google Scholar
    • Export Citation
  • 11.

    Lagergren J, Bergström R, Lindgren A, . The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340–346.

    • Search Google Scholar
    • Export Citation
  • 12.

    Freedman ND, Abnet CC, Leitzmann MF, . A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424–1433.

    • Search Google Scholar
    • Export Citation
  • 13.

    Rice TW, Apperson-Hansen C, DiPaola LM, . Worldwide Esophageal Cancer Collaboration: clinical staging data. Dis Esophagus 2016;29:707–714.

    • Search Google Scholar
    • Export Citation
  • 14.

    Rice TW, Gress DM, Patil DT, . Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:304–317.

    • Search Google Scholar
    • Export Citation
  • 15.

    Kim TJ, Kim HY, Lee KW, . Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009;29:403–421.

    • Search Google Scholar
    • Export Citation
  • 16.

    Siewert JR, Stein H. Carcinoma of the cardia: carcinoma of the gastroesophageal junction - classification, pathology, and extent of resection. Dis Esophagus 1996;9:173–182.

    • Search Google Scholar
    • Export Citation
  • 17.

    Rüdiger Siewert J, Feith M, Werner M, . Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353–361.

    • Search Google Scholar
    • Export Citation
  • 18.

    Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012;136:691–697.

    • Search Google Scholar
    • Export Citation
  • 19.

    Moelans CB, van Diest PJ, Milne AN, . Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathol Res Int 2010;2011:674182.

    • Search Google Scholar
    • Export Citation
  • 20.

    Kato S, Okamura R, Baumgartner JM, . Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res 2018;24:6248–6256.

    • Search Google Scholar
    • Export Citation
  • 21.

    Dreilich M, Wanders A, Brattström D, . HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19:224–231.

    • Search Google Scholar
    • Export Citation
  • 22.

    Reichelt U, Duesedau P, Tsourlakis MC, . Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120–129.

    • Search Google Scholar
    • Export Citation
  • 23.

    Schoppmann SF, Jesch B, Friedrich J, . Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010;34:1868–1873.

  • 24.

    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523–1529.

  • 25.

    Tanner M, Hollmén M, Junttila TT, . Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273–278.

    • Search Google Scholar
    • Export Citation
  • 26.

    Bang YJ, Van Cutsem E, Feyereislova A, . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.

    • Search Google Scholar
    • Export Citation
  • 27.

    Bang Y, Chung H, Xu J, . Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol 2009;27: Abstract 4556.

    • Search Google Scholar
    • Export Citation
  • 28.

    Bartley AN, Washington MK, Colasacco C, . HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:446–464.

    • Search Google Scholar
    • Export Citation
  • 29.

    Hofmann M, Stoss O, Shi D, . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797–805.

    • Search Google Scholar
    • Export Citation
  • 30.

    Rüschoff J, Dietel M, Baretton G, . HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299–307.

    • Search Google Scholar
    • Export Citation
  • 31.

    U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Available at: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm. Accessed February 21, 2019.

    • Export Citation
  • 32.

    Le DT, Durham JN, Smith KN, . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–413.

    • Search Google Scholar
    • Export Citation
  • 33.

    Murphy KM, Zhang S, Geiger T, . Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 2006;8:305–311.

    • Search Google Scholar
    • Export Citation
  • 34.

    Bartley AN, Fitzgibbons PL, Broaddus RR, . Template for reporting results of DNA mismatch repair testing in patients being considered for checkpoint inhibitor immunotherapy. Northfield, Illinois: College of American Pathologists; 2018.

  • 35.

    U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. 2017. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm. Accessed February 21, 2019.

    • Export Citation
  • 36.

    Fuchs CS, Doi T, Jang RW, . Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.

    • Search Google Scholar
    • Export Citation
  • 37.

    Kojima T, Muro K, Francois E, . Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol 2019;37(4_suppl):2.

    • Search Google Scholar
    • Export Citation
  • 38.

    van Hagen P, Hulshof MC, van Lanschot JJ, . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

    • Search Google Scholar
    • Export Citation
  • 39.

    Ychou M, Boige V, Pignon J-P, . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721.

    • Search Google Scholar
    • Export Citation
  • 40.

    Al-Batran SE, Hofheinz RD, Pauligk C, . Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697–1708.

    • Search Google Scholar
    • Export Citation
  • 41.

    Steyerberg EW, Neville BA, Koppert LB, . Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:4277–4284.

    • Search Google Scholar
    • Export Citation
  • 42.

    Tirumani H, Rosenthal MH, Tirumani SH, . Esophageal carcinoma: current concepts in the role of imaging in staging and management. Can Assoc Radiol J 2015;66:130–139.

    • Search Google Scholar
    • Export Citation
  • 43.

    Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? Semin Oncol 2004;31:444–449.

    • Search Google Scholar
    • Export Citation
  • 44.

    Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg 2006;95:260–269.

  • 45.

    de Graaf GW, Ayantunde AA, Parsons SL, . The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007;33:988–992.

    • Search Google Scholar
    • Export Citation
  • 46.

    Nath J, Moorthy K, Taniere P, . Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 2008;95:721–726.

    • Search Google Scholar
    • Export Citation
  • 47.

    Peyre CG, Hagen JA, DeMeester SR, . Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008;248:979–985.

    • Search Google Scholar
    • Export Citation
  • 48.

    Rizk NP, Ishwaran H, Rice TW, . Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010;251:46–50.

  • 49.

    Groth SS, Virnig BA, Whitson BA, . Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg 2010;139:612–620.

    • Search Google Scholar
    • Export Citation
  • 50.

    Coccolini F, Nardi M, Montori G, . Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg 2018;51:120–127.

    • Search Google Scholar
    • Export Citation
  • 51.

    Al-Batran SE, Lorenzen S. Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? Hematol Oncol Clin North Am 2017;31:441–452.

    • Search Google Scholar
    • Export Citation
  • 52.

    Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110–4117.

  • 53.

    Alderson D, Cunningham D, Nankivell M, . Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol 2017;18:1249–1260.

    • Search Google Scholar
    • Export Citation
  • 54.

    Smalley SR, Benedetti JK, Haller DG, . Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–2333.

    • Search Google Scholar
    • Export Citation
  • 55.

    Macdonald JS, Smalley SR, Benedetti J, . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.

    • Search Google Scholar
    • Export Citation
  • 56.

    Noh SH, Park SR, Yang HK, .Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389–1396.

    • Search Google Scholar
    • Export Citation
  • 57.

    Conroy T, Galais M-P, Raoul J-L, . Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305–314.

    • Search Google Scholar
    • Export Citation
  • 58.

    Minsky BD, Pajak TF, Ginsberg RJ, . INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–1174.

    • Search Google Scholar
    • Export Citation
  • 59.

    Li QQ, Liu MZ, Hu YH, . Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus 2010;23:253–259.

    • Search Google Scholar
    • Export Citation
  • 60.

    Day FL, Leong T, Ngan S, . Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer 2011;104:265–271.

    • Search Google Scholar
    • Export Citation
  • 61.

    Iyer R, Wilkinson N, Demmy T, . Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 2004;11:665–673.

    • Search Google Scholar
    • Export Citation
  • 62.

    Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538–543.

    • Search Google Scholar
    • Export Citation
  • 63.

    Fiorica F, Di Bona D, Schepis F, . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925–930.

    • Search Google Scholar
    • Export Citation
  • 64.

    Ma HF, Lv GX, Cai ZF, . Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis. OncoTargets Ther 2018;11:3441–3447.

    • Search Google Scholar
    • Export Citation
  • 65.

    Sjoquist KM, Burmeister BH, Smithers BM, . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–692.

    • Search Google Scholar
    • Export Citation
  • 66.

    Swisher SG, Hofstetter W, Komaki R, . Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 2010;90:892–898[discussion 898–899].

    • Search Google Scholar
    • Export Citation
  • 67.

    Zhao X, Ren Y, Hu Y, . Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS One 2018;13:e0202185.

    • Search Google Scholar
    • Export Citation
  • 68.

    Oppedijk V, van der Gaast A, van Lanschot JJ, . Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol 2014;32:385–391.

    • Search Google Scholar
    • Export Citation
  • 69.

    Noordman BJ, Verdam MGE, Lagarde SM, . Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial. J Clin Oncol 2018;36:268–275.

    • Search Google Scholar
    • Export Citation
  • 70.

    Shapiro J, van Lanschot JJB, Hulshof MCCM, . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–1098.

    • Search Google Scholar
    • Export Citation
  • 71.

    Leichman LP, Goldman BH, Bohanes PO, . S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011;29:4555–4560.

    • Search Google Scholar
    • Export Citation
  • 72.

    Khushalani NI, Leichman CG, Proulx G, . Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844–2850.

    • Search Google Scholar
    • Export Citation
  • 73.

    Tepper J, Krasna MJ, Niedzwiecki D, . Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–1092.

    • Search Google Scholar
    • Export Citation
  • 74.

    Bedenne L, Michel P, Bouché O, . Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–1168.

    • Search Google Scholar
    • Export Citation
  • 75.

    Sharma R, Yang GY, Nava HR, . A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. J Clin Oncol 2009;27:e15619.

    • Search Google Scholar
    • Export Citation
  • 76.

    Ajani JA, Winter K, Okawara GS, . Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953–3958.

    • Search Google Scholar
    • Export Citation
  • 77.

    Cunningham D, Allum WH, Stenning SP, . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

    • Search Google Scholar
    • Export Citation
  • 78.

    Al-Batran S-E, Homann N, Pauligk C, . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948–1957.

    • Search Google Scholar
    • Export Citation
  • 79.

    Kofoed SC, Muhic A, Baeksgaard L, . Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg 2012;101:26–31.

    • Search Google Scholar
    • Export Citation
  • 80.

    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727–1733.

    • Search Google Scholar
    • Export Citation
  • 81.

    Allum WH, Stenning SP, Bancewicz J, . Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062–5067.

    • Search Google Scholar
    • Export Citation
  • 82.

    Boonstra JJ, Kok TC, Wijnhoven BP, . Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011;11:181..

    • Search Google Scholar
    • Export Citation
  • 83.

    Ruppert BN, Watkins JM, Shirai K, . Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010;33:346–352.

    • Search Google Scholar
    • Export Citation
  • 84.

    Herskovic A, Martz K, al-Sarraf M, . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593–1598.

    • Search Google Scholar
    • Export Citation
  • 85.

    Cooper JS, Guo MD, Herskovic A, . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623–1627.

    • Search Google Scholar
    • Export Citation
  • 86.

    Bascoul-Mollevi C, Gourgou S, Galais MP, . Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer 2017;84:239–249.

    • Search Google Scholar
    • Export Citation
  • 87.

    Bang YJ, Kim YW, Yang HK, . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315–321.

    • Search Google Scholar
    • Export Citation
  • 88.

    Ford HE, Marshall A, Bridgewater JA, . Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78–86.

    • Search Google Scholar
    • Export Citation
  • 89.

    Thuss-Patience PC, Kretzschmar A, Bichev D, . Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306–2314.

    • Search Google Scholar
    • Export Citation
  • 90.

    Janmaat VT, Steyerberg EW, van der Gaast A, . Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 2017;11:CD004063.

    • Search Google Scholar
    • Export Citation
  • 91.

    Al-Batran S-E, Hartmann JT, Probst S, . Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435–1442.

    • Search Google Scholar
    • Export Citation
  • 92.

    Enzinger PC, Burtness BA, Niedzwiecki D, . CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016;34:2736–2742.

    • Search Google Scholar
    • Export Citation
  • 93.

    Kim GM, Jeung HC, Rha SY, . A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012;48:518–526.

    • Search Google Scholar
    • Export Citation
  • 94.

    Lorenzen S, Schuster T, Porschen R, . Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667–1673.

    • Search Google Scholar
    • Export Citation
  • 95.

    Bouché O, Raoul JL, Bonnetain F, . Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004;22:4319–4328.

    • Search Google Scholar
    • Export Citation
  • 96.

    Kang YK, Kang WK, Shin DB, . Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666–673.

    • Search Google Scholar
    • Export Citation
  • 97.

    Park YH, Lee JL, Ryoo BY, . Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 2008;61:623–629.

    • Search Google Scholar
    • Export Citation
  • 98.

    Luo HY, Xu RH, Wang F, . Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 2010;56:94–100.

    • Search Google Scholar
    • Export Citation
  • 99.

    Okines AFC, Norman AR, McCloud P, . Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529–1534.

    • Search Google Scholar
    • Export Citation
  • 100.

    Ajani JA, Fodor MB, Tjulandin SA, . Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660–5667.

    • Search Google Scholar
    • Export Citation
  • 101.

    Van Cutsem E, Moiseyenko VM, Tjulandin S, . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997.

    • Search Google Scholar
    • Export Citation
  • 102.

    Van Cutsem E, Boni C, Tabernero J, . Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 2015;26:149–156.

    • Search Google Scholar
    • Export Citation
  • 103.

    Shah MA, Janjigian YY, Stoller R, . Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol 2015;33:3874–3879.

    • Search Google Scholar
    • Export Citation
  • 104.

    Blum Murphy MA, Qiao W, Mewada N, . A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. Am J Clin Oncol 2018;41:321–325.

    • Search Google Scholar
    • Export Citation
  • 105.

    Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. J Clin Oncol 2005;23(Suppl 16):4014.

    • Search Google Scholar
    • Export Citation
  • 106.

    Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004; 18(14, Suppl 14)22–25.

    • Search Google Scholar
    • Export Citation
  • 107.

    Dank M, Zaluski J, Barone C, . Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450–1457.

    • Search Google Scholar
    • Export Citation
  • 108.

    Wolff K, Wein A, Reulbach U, . Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs 2009;20:165–173.

    • Search Google Scholar
    • Export Citation
  • 109.

    Burtness B, Gibson M, Egleston B, . Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009;20:1242–1248.

    • Search Google Scholar
    • Export Citation
  • 110.

    Lustberg MB, Bekaii-Saab T, Young D, . Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713–718.

    • Search Google Scholar
    • Export Citation
  • 111.

    Moehler M, Kanzler S, Geissler M, . A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21:71–77.

    • Search Google Scholar
    • Export Citation
  • 112.

    Guimbaud R, Louvet C, Ries P, . Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520–3526.

    • Search Google Scholar
    • Export Citation
  • 113.

    Ilson DH, Forastiere A, Arquette M, . A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316–323.

    • Search Google Scholar
    • Export Citation
  • 114.

    Petrasch S, Welt A, Reinacher A, . Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511–514.

    • Search Google Scholar
    • Export Citation
  • 115.

    Gadgeel SM, Shields AF, Heilbrun LK, . Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37–41.

    • Search Google Scholar
    • Export Citation
  • 116.

    Kim JY, Do YR, Park KU, . A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 2010;66:31–36.

    • Search Google Scholar
    • Export Citation
  • 117.

    Ohtsu A, Shimada Y, Shirao K, . Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54–59.

    • Search Google Scholar
    • Export Citation
  • 118.

    Hong YS, Song SY, Lee SI, . A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004;15:1344–1347.

    • Search Google Scholar
    • Export Citation
  • 119.

    Albertsson M, Johansson B, Friesland S, . Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol 2007;24:407–412.

    • Search Google Scholar
    • Export Citation
  • 120.

    Ajani JA, Ilson DH, Daugherty K, . Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086–1091.

    • Search Google Scholar
    • Export Citation
  • 121.

    Ilson DH, Wadleigh RG, Leichman LP, . Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898–902.

    • Search Google Scholar
    • Export Citation
  • 122.

    Ross P, Nicolson M, Cunningham D, . Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996–2004.

    • Search Google Scholar
    • Export Citation
  • 123.

    Sumpter K, Harper-Wynne C, Cunningham D, . Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92:1976–1983.

    • Search Google Scholar
    • Export Citation
  • 124.

    Cunningham D, Starling N, Rao S, . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.

  • 125.

    Fuchs CS, Tomasek J, Yong CJ, . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31–39.

    • Search Google Scholar
    • Export Citation
  • 126.

    Wilke H, Muro K, Van Cutsem E, . Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–1235.

    • Search Google Scholar
    • Export Citation
  • 127.

    Le DT, Uram JN, Wang H, . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  • 128.

    Hironaka S, Ueda S, Yasui H, . Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31:4438–4444.

    • Search Google Scholar
    • Export Citation
  • 129.

    Sym SJ, Hong J, Park J, . A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013;71:481–488.

    • Search Google Scholar
    • Export Citation
  • 130.

    Fuchs CS, Moore MR, Harker G, . Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807–814.

    • Search Google Scholar
    • Export Citation
  • 131.

    Sym SJ, Ryu MH, Lee JL, . Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol 2008;31:151–156.

    • Search Google Scholar
    • Export Citation
  • 132.

    Assersohn L, Brown G, Cunningham D, . Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:64–69.

    • Search Google Scholar
    • Export Citation
  • 133.

    Maugeri-Saccà M, Pizzuti L, Sergi D, . FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013;32:67.

    • Search Google Scholar
    • Export Citation
  • 134.

    Shitara K, Doi T, Dvorkin M, . Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1437–1448.

    • Search Google Scholar
    • Export Citation
  • 135.

    U.S. Food and Drug Administration. FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma. 2019. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm632032.htm. Accessed March 6, 2019.

    • Export Citation
  • 136.

    Bando H, Doi T, Muro K, . A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer 2016;62:46–53.

    • Search Google Scholar
    • Export Citation
  • 137.

    U.S. Food and Drug Administration. FDA approves trastuzumab (Herceptin) 2010. Available at: http://wayback.archive-it.org/7993/20170113081145/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm230418.htm. Accessed February 21, 2019.

  • 138.

    U.S. Food and Drug Administration. Ramucirumab in combination with paclitaxel. 2014. Available at: http://wayback.archive-it.org/7993/20170111231651/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm421930.htm. Accessed February 21, 2019.

    • Export Citation
  • 139.

    U.S. Food and Drug Administration. Ramucirumab. 2014. Available at: http://wayback.archive-it.org/7993/20170111231700/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm. Accessed February 21, 2019.

  • 140.

    Le DT, Uram JN, Wang H, . PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 2016;34(4_suppl):195.

    • Search Google Scholar
    • Export Citation
  • 141.

    Soularue É, Cohen R, Tournigand C, . Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bull Cancer 2015;102:324–331.

    • Search Google Scholar
    • Export Citation
  • 142.

    Tabernero J, Ohtsu A, Muro K, . Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment of advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 2017;16:2215–2222.

    • Search Google Scholar
    • Export Citation
  • 143.

    Fuchs CS, Shitara K, Di Bartolomeo M, . Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:420–435.

    • Search Google Scholar
    • Export Citation
  • 144.

    Muro K, Chung HC, Shankaran V, . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717–726.

    • Search Google Scholar
    • Export Citation
  • 145.

    Bang Y-J, Muro K, Fuchs CS, . KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. J Clin Oncol 2017;35(15_suppl):4012.

    • Search Google Scholar
    • Export Citation
  • 146.

    Wainberg ZA, Jalal S, Muro K, . KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Ann Oncol 2017;28(suppl_5):v605–v649.

    • Search Google Scholar
    • Export Citation
  • 147.

    Catenacci DV, Wainberg Z, Fuchs CS, . KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. Ann Oncol 2017;28:suppl_3.

  • 148.

    Kato K, Shah MA, Enzinger P, . KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol 2019;15:1057–1066.

    • Search Google Scholar
    • Export Citation
  • 149.

    Shitara K, Özgüroğlu M, Bang Y-J, . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123–133.

    • Search Google Scholar
    • Export Citation
  • 150.

    Doi T, Piha-Paul SA, Jalal SI, . Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol 2018;36:61–67.

    • Search Google Scholar
    • Export Citation
  • 151.

    Shah MA, Kojima T, Hochhauser D, . Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study [published online December 20, 2018]. JAMA Oncol. doi: 10.1001/jamaoncol.2018.5441

    • Search Google Scholar
    • Export Citation
  • 152.

    Meerten EV, van Rij C, Tesselaar ME, . Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study. J Clin Oncol 2010;28(15_suppl):e14508.

    • Search Google Scholar
    • Export Citation
  • 153.

    van Westreenen HL, Westerterp M, Bossuyt PMM, . Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:3805–3812.

    • Search Google Scholar
    • Export Citation
  • 154.

    Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 2006;21:137–145.

    • Search Google Scholar
    • Export Citation
  • 155.

    Lou F, Sima CS, Adusumilli PS, . Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol 2013;8:1558–1562.

    • Search Google Scholar
    • Export Citation
  • 156.

    Sudo K, Taketa T, Correa AM, . Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 2013;31:4306–4310.

    • Search Google Scholar
    • Export Citation
  • 157.

    Dorth JA, Pura JA, Palta M, . Patterns of recurrence after trimodality therapy for esophageal cancer. Cancer 2014;120:2099–2105.

  • 158.

    Sudo K, Xiao L, Wadhwa R, . Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014;32:3400–3405.

    • Search Google Scholar
    • Export Citation
  • 159.

    Taketa T, Sudo K, Correa AM, . Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 2014;12:1139–1144.

    • Search Google Scholar
    • Export Citation
  • 160.

    MacLeod CM, (ed), The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. New York: Columbia University Press 1949:199.

    • Export Citation
  • 161.

    Oken MM, Creech RH, Tormey DC, . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.

    • Search Google Scholar
    • Export Citation
  • 162.

    Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187–193.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3985 3985 696
PDF Downloads 1634 1634 313
EPUB Downloads 0 0 0